Potential role of Carvedilol in the cardiac immune response induced by experimental infection with Trypanosoma cruzi.
No Thumbnail Available
Date
2017
Authors
Horta, Aline Luciano
Leite, Ana Luísa Junqueira
Costa, Guilherme de Paula
Figueiredo, Vivian Paulino
Silva, André Talvani Pedrosa da
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Trypanosoma cruzi causes a cardiac infection characterized by an inflammatory imbalance that could become the inciting factor
of the illness. To this end, we evaluated the role of carvedilol, a beta-blocker with potential immunomodulatory properties, on the
immune response in C57BL/6 mice infected with VL-10 strain of T. cruzi in the acute phase. Animals (𝑛 = 40) were grouped: (i) not
infected, (ii) infected, (iii) infected + carvedilol, and (iv) not infected + carvedilol.We analyzed parameters related to parasitemia,
plasma levels of TNF, IL-10, and CCL2, and cardiac histopathology after the administration of carvedilol for 30 days. We did not
observe differences in the maximum peaks of parasitemia in the day of their detection among the groups. The plasma TNF was
elevated at 60 days of infection in mice treated or not with carvedilol. However, we observed a decreased CCL2 level and increased
IL-10 levels in those infected animals treated with carvedilol, which impacted the reduction of the inflammatory infiltration in
cardiac tissue. For this experimentalmodel, carvedilol therapy was not able to alter the levels of circulating parasites butmodulates
the pattern of CCL2 and IL-10 mediators when the VL10 strain of T. cruzi was used in C57BL6 mice.
Description
Keywords
Citation
HORTA, A. L. et al. Potential role of Carvedilol in the cardiac immune response induced by experimental infection with Trypanosoma cruzi. BioMed Research International, v. 2017, p. 1-7, 2017. Disponível em: <https://www.hindawi.com/journals/bmri/2017/9205062/>. Acesso em: 15 set. 2017.